An editorial notes that when put in perspective with historical data in this setting (5-year survival of <5% in stage 4 disease) and the control groups of the CheckMate trials (4-year overall survival of 5%), these results give hope for a long-term plateau in overall survival of around 15%, which is three-times higher than survival values before the immunotherapy era. It adds that the analysis provides interesting data on late toxicity and strongly suggest that patients should be monitored for—and their treating physicians should be acutely conscious of—treatment-related adverse events for the entire duration of exposure. However, unlike chemotherapy, there does not appear to be any cumulative toxicity with immunotherapy. A remaining question is the optimal duration of immune checkpoint inhibitor treatment for patients with objective response.